Latest:
Exploring Real-World Evidence Presented at ATA 2023
Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Macarena de la Fuente, MD
Macarena de la Fuente, MD, is an associate professor of neuro-oncology, chief of the Neuro-Oncology Division, clinical service leader for Neuro-Oncology Service Line - Sylvester Comprehensive Cancer Center, chair of the Neuro-Oncology Site Disease Group, director of the Neuro-Oncology Fellowship Program, and oncology clinical service leader for Neuro-Oncology at the Miller School of Medicine of University of Miami in Florida.
Latest:
Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma
Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.
Kirollos Hanna, PharmD, BCPS, BCOP
Latest:
Comorbidities, Quality of Life, Efficacy, and Safety in Expanding Subcutaneous Treatment Use
Panelists discuss how subcutaneous checkpoint inhibitors are appropriate for nearly all patients except those with severe cachexia limiting injection sites, with patient conversations emphasizing equivalent efficacy data, safety profiles, quality of life benefits including potential home administration, and the option to maintain IV therapy for patients who prefer their current regimen.
Young Son, PGY3
Latest:
Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer
Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.
Lorraine Scanlon, MD
Lorraine Scanlon, MD, is an SUO fellow at London Health Sciences Center in London, Ontario, Canada
Latest:
Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC
Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.
Richard L. Martin III, MD, MPH
Latest:
A Challenge to Medical Oncology Training Programs: Promote Equity in Training
In her 2020 American Society of Clinical Oncology presidential address, “Equity: Every patient. Every day. Everywhere,” Lori J. Pierce, MD, challenges medical oncology to imagine a future when equity is considered a humanistic standard of oncology practice.
Michael J. Fallon, MD
Latest:
Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma
Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.